You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

ARMONAIR RESPICLICK Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Armonair Respiclick patents expire, and when can generic versions of Armonair Respiclick launch?

Armonair Respiclick is a drug marketed by Teva Pharm and is included in one NDA. There are thirteen patents protecting this drug.

This drug has three hundred and three patent family members in thirty-two countries.

The generic ingredient in ARMONAIR RESPICLICK is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-six suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Armonair Respiclick

A generic version of ARMONAIR RESPICLICK was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for ARMONAIR RESPICLICK?
  • What are the global sales for ARMONAIR RESPICLICK?
  • What is Average Wholesale Price for ARMONAIR RESPICLICK?
Drug patent expirations by year for ARMONAIR RESPICLICK
Drug Prices for ARMONAIR RESPICLICK

See drug prices for ARMONAIR RESPICLICK

Pharmacology for ARMONAIR RESPICLICK

US Patents and Regulatory Information for ARMONAIR RESPICLICK

ARMONAIR RESPICLICK is protected by thirteen US patents and three FDA Regulatory Exclusivities.

Patents protecting ARMONAIR RESPICLICK

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having an anti-reverse rotation actuator
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Airflow adaptor for a breath-actuated dry powder inhaler
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counters for inhalers, inhalers and methods of assembly thereof
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dry powder inhalation apparatus
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Process for preparing a medicament
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Dose counter for inhaler having a bore and shaft arrangement
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

FDA Regulatory Exclusivity protecting ARMONAIR RESPICLICK

NEW STRENGTH
Exclusivity Expiration: ⤷  Sign Up

PEDIATRIC EXCLUSIVITY
Exclusivity Expiration: ⤷  Sign Up

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ARMONAIR RESPICLICK

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-001 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-001 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-002 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
Teva Pharm ARMONAIR RESPICLICK fluticasone propionate POWDER;INHALATION 208798-003 Jan 27, 2017 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for ARMONAIR RESPICLICK

See the table below for patents covering ARMONAIR RESPICLICK around the world.

Country Patent Number Title Estimated Expiration
South Korea 101628934 ⤷  Sign Up
China 102655902 Airflow adaptor for a breath-actuated dry powder inhaler ⤷  Sign Up
South Korea 20130103825 DOSE COUNTERS FOR INHALERS, INHALERS AND SHAFTS THEREOF ⤷  Sign Up
Poland 2514465 ⤷  Sign Up
South Korea 101618932 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for ARMONAIR RESPICLICK

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2506844 132018000000341 Italy ⤷  Sign Up PRODUCT NAME: UN PRODOTTO DI COMBINAZIONE FARMACEUTICA COMPRENDENTE UN SALE FARMACEUTICAMENTE ACCETTABILE DI UMECLIDINIO (AD ESEMPIO BROMURO DI UMECLIDINIO), VILANTEROLO O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE (AD ESEMPIO VILANTEROLO TRIFENATATO) E UN FUROATO(TRELEGY ELLIPTA - FLUTICASONE FUROATO/UMECLIDINIO/VILANTEROLO); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/17/1236, 20171117
2506844 SPC/GB18/020 United Kingdom ⤷  Sign Up PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117
1519731 132013902182575 Italy ⤷  Sign Up PRODUCT NAME: AZELASTINA CLORIDRATO/FLUTICASONE PROPIONATO(DYMISTA); AUTHORISATION NUMBER(S) AND DATE(S): 2011/07125-REG, 20111024;041808015/M-027/M-039/M-041/M, 20130527
1305329 SPC/GB08/026 United Kingdom ⤷  Sign Up PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116
2506844 2018C/022 Belgium ⤷  Sign Up PRODUCT NAME: EEN FARMACEUTISCH COMBINATIEPRODUCT DAT EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN UMECLIDINIUM (BV. UMECLIDINIUMBROMIDE), VILANTEROL OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN (BV. VILANTEROLTRIFENATAAT) EN FLUTICASONEFUROAAT OMVAT; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.